Replies to post #532999 on NorthWest Biotherapeutics Inc (NWBO)

[RPD60]

HyGro,

You have made yourself clear that FDA will not be fooled by obvious trial manipulation etc that you claim occurred. But how do you square the fact that SNO gave Dr Liau a Plenary Lecture on this severely flawed trial at one of the most revered oncology conferences in the world? This would mean that no Oncologists who reviewed Dr Liaus abstract has any clue about the trial and all of its manipulations and, in effect, they are being duped.

Do you believe that?

Or is it possible that her peers see great promise in the trial results, however flawed, such that the trial is still worthy of a Plenary Lecture?

Final question—how does manipulating the trial and changing the endpoints and statistical plans etc enable people to live longer? Because if that is the secret then more trials should be run this way!

[Roman516]

The FDA will have a very clear view of the fact that DCVax-L works.
Plus, the fact that when other compounds are added to DCVax-L, that DCVax-L is even more effective.

[SkyLimit2022]

Thanks for requesting more information about the NIH grants awarded to UCLA.

Please review the full-context sources below:

https://connect.uclahealth.org/2021/03/22/ucla-received-590-million-in-nih-funding-second-highest-total-for-academic-medical-centers-in-2020/

https://newsroom.ucla.edu/releases/nih-grant-lab-gene-cell-therapies

https://connect.uclahealth.org/2022/09/14/brain-cancer-discovery-clinical-trials/



The phase 3 clinical trial results are summarized at the full-context sources linked below, and the results will be presented with a more comprehensive analysis in the forthcoming independent peer review.

https://academic.oup.com/neuro-oncology/article/24/Supplement_7/vii66/6826190?login=false

https://virtualtrials.org/dcvax.cfm

$nwbo pic.twitter.com/bKa1n3BJPU

— Blake (@MC17595091) November 16, 2022

[SkyLimit2022]

Thanks for posting.

Ashkan’s statement was in June 2022. Skip to minute 15:15

Dr. Ashkan was the chief investigator of the murcidencel trial for patients in Europe. At King’s College in London, Ashkan is the lead clinician for neuro-oncology and the chair of the King’s Neurosciences Clinical Trial Unit. He is a world-renowned cancer trial expert. A few years ago, Professor Ashkan was named the UK Clinician of the Year by The Brain Tumour Charity. Additionally, Ashkan serves as an advisor to the U.K. government.

https://www.kcl.ac.uk/people/keyoumars-ashkan

https://www.annalsofoncology.org/article/S0923-7534(22)00006-0/fulltext

https://academic.oup.com/neuro-oncology/article/24/Supplement_7/vii66/6826190?login=false

$nwbo pic.twitter.com/bKa1n3BJPU

— Blake (@MC17595091) November 16, 2022